Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Zealand Pharma A/S Announces New Preclinical Data on GLP-1-Gastrin Dual Agonis


Thursday, 26 Sep 2013 08:00am EDT 

Zealand Pharma A/S announced that new preclinical data on ZP3022, a peptide receptor agonist from the Company‚Äôs GLP-1-gastrin dual agonist program, shows potential as an approach for the treatment and/or prevention of type 2 diabetes. Data presented earlier have shown that treatment with the GLP-1-gastrin dual agonist ZP3022 improves the glycemic control and glucose tolerance in preclinical models of type 2 diabetes (db/db mice and Zucker Diabetic Fatty (ZDF) rats). These results were accompanied by a significant increase in beta cell mass, which was also significant compared to liraglutide. The studies presented on September 26, 2013 investigated the in-vitro effects of ZP3022 on the regulation of pancreatic beta cell proliferation, on pancreatic islets cell survival and on the functional capacity of beta cells in isolated rat islets of Langerhans. The study findings demonstrate that this GLP-1-gastrin dual agonist significantly increases beta cell proliferation, reduces apoptosis and enhances glucose-stimulated insulin secretion